Assignee
SHANGHAI JUNSHI BIOSCIENCES CO LTD
CN·3 granted patents·26 pending applications·1 citations·filing 2018–2023
Top patents by PatentIndex Score
29 records- 0178US12110329B2Anti-BTLA antibodySHANGHAI JUNSHI BIOSCIENCES CO LTD·Filed 2021·Granted Oct 8, 2024·1 cites·15 claims
- 0260US2025346674A1Combination of anti-pd-1 antibody and anti-egfr antibody, and use thereof in treatment of head and neck squamous cell carcinomaSHANGHAI JUNSHI BIOSCIENCES CO LTD·Filed 2023·Application pending·0 cites
- 0360US2023322929A1Compositions and Methods for Treating Solid Tumors with Anti-BTLA as Mono or Combination TherapySHANGHAI JUNSHI BIOSCIENCES CO LTD·Filed 2023·Application pending·0 cites
- 0458US2025333730A1Sirna for inhibiting angptl3 gene expression and use thereofSHANGHAI JUNSHI BIOSCIENCES CO LTD·Filed 2022·Application pending·0 cites
- 0557US2024117043A1Bispecific antibody targeting cd112r and tigit and use thereofSHANGHAI JUNSHI BIOSCIENCES CO LTD·Filed 2023·Application pending·0 cites
- 0656US2025034254A1Use of anti-pd-1 antibody in combination with chemotherapy in treating esophageal cancerSHANGHAI JUNSHI BIOSCIENCES CO LTD·Filed 2022·Application pending·0 cites
- 0755US2024218066A1Use of anti-pd-1 antibody in combination with first-line chemotherapy in treatment of advanced non-small cell lung cancerSHANGHAI JUNSHI BIOSCIENCES CO LTD·Filed 2022·Application pending·0 cites
- 0853US2023192854A1Anti-btla antibody pharmaceutical composition and use thereofSHANGHAI JUNSHI BIOSCIENCES CO LTD·Filed 2022·Application pending·0 cites
- 0953US2024254230A1Method of treating urothelial carcinomaSHANGHAI JUNSHI BIOSCIENCES CO LTD·Filed 2022·Application pending·0 cites
- 1053US2025122271A1Anti-dkk1 antibody, pharmaceutical composition thereof, and use thereofSHANGHAI JUNSHI BIOSCIENCES CO LTD·Filed 2023·Application pending·0 cites
- 1152US2025154275A1Anti-cd3 and anti-cd20 bispecific antibody and use thereofSHANGHAI JUNSHI BIOSCIENCES CO LTD·Filed 2023·Application pending·0 cites
- 1252US2024309087A1Anti-cd112r antibody and use thereofSHANGHAI JUNSHI BIOSCIENCES CO LTD·Filed 2022·Application pending·0 cites
- 1352US2023322930A1Use of an anti-pd-1 antibody and a cytotoxic anticancer drug in treatment of non-small cell lung cancerSHANGHAI JUNSHI BIOSCIENCES CO LTD·Filed 2021·Application pending·0 cites
- 1452US2023365691A1Use of anti-pd-1 antibody in treatment of nasopharyngeal carcinomaSHANGHAI JUNSHI BIOSCIENCES CO LTD·Filed 2021·Application pending·0 cites
- 1551US2023082898A1Use of anti-pd-1 antibody in treatment of tumorsSHANGHAI JUNSHI BIOSCIENCES CO LTD·Filed 2021·Application pending·0 cites
- 1651US2025127915A1Anti-cldn-18.2 antibody-drug conjugate and use thereofSHANGHAI JUNSHI BIOSCIENCES CO LTD·Filed 2022·Application pending·0 cites
- 1750US2023212292A1Use of anti-pd-1 antibody in treating neuroendocrine tumorsSHANGHAI JUNSHI BIOSCIENCES CO LTD·Filed 2021·Application pending·0 cites
- 1850US2023212278A1Pharmaceutical composition of anti-il-17a antibodies and use thereofSHANGHAI JUNSHI BIOSCIENCES CO LTD·Filed 2021·Application pending·0 cites
- 1950US2024067720A1Anti-tigit antibody pharmaceutical composition and application thereofSHANGHAI JUNSHI BIOSCIENCES CO LTD·Filed 2022·Application pending·0 cites
- 2049US2024342083A1Anti-pd-1 antibody pharmaceutical composition and use thereofSHANGHAI JUNSHI BIOSCIENCES CO LTD·Filed 2022·Application pending·0 cites
- 2149US2023107856A1Use of anti-pd-1 antibody in treatment of malignancySHANGHAI JUNSHI BIOSCIENCES CO LTD·Filed 2021·Application pending·0 cites
- 2248US2022363754A1Anti-tigit antibodies and application thereofSHANGHAI JUNSHI BIOSCIENCES CO LTD·Filed 2020·Application pending·0 cites
- 2347US12209124B2Anti-IL-17A antibody and use thereofSHANGHAI JUNSHI BIOSCIENCES CO LTD·Filed 2019·Granted Jan 28, 2025·0 cites·15 claims
- 2447US2024059771A1Anti-cldn-18.2 antibody and use thereofSHANGHAI JUNSHI BIOSCIENCES CO LTD·Filed 2021·Application pending·0 cites
- 2547US2023295301A1Anti-ctla-4 antibody and use thereofSHANGHAI JUNSHI BIOSCIENCES CO LTD·Filed 2021·Application pending·0 cites
- 2646US2022154296A1Use of anti-pd-1 antibody in preparation of medicament for treating solid tumorsSHANGHAI JUNSHI BIOSCIENCES CO LTD·Filed 2020·Application pending·0 cites
- 2743US2021393777A1Stable preparation comprising anti-pcsk9 antibodySHANGHAI JUNSHI BIOSCIENCES CO LTD·Filed 2019·Application pending·0 cites
- 2841US2023073183A1Improved uricase and method for treating hyperuricemia using sameSHANGHAI JUNSHI BIOSCIENCES CO LTD·Filed 2020·Application pending·0 cites
- 2937US11267890B2Anti-PD-L1 antibody and application thereofSHANGHAI JUNSHI BIOSCIENCES CO LTD·Filed 2018·Granted Mar 8, 2022·0 cites·17 claims
Join the waitlist — get patent alerts
Get an alert when SHANGHAI JUNSHI BIOSCIENCES CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →